Depakote ER in Borderline Personality Disorder

This study examines the effect of Depakote ER versus placebo in a randomized trial of borderline personality disorder. Patients all participate in DBT therapy and those who are not responsive are assigned to either Depakote ER or placebo for up to 12 weeks. Borderline Personality Symtoms are measured and side-effects are assessed.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Borderline Personality Disorder Mental Disorders Personality Disorders

Age range

21 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Male or female patients with the diagnosis of borderline personality disorder between the ages of 21 adn 55 years old. Must be in good physical health -

Exclusion criteria

Major psychiatric illness on Axis I - schizophrenia or bipolar disorder. May not have current MDD. May not be dependent on illicit substances or alcohol.

Treatment and study plan

Depakote ER

Drug

Primary outcomes

Symptom Checklist 90

Secondary outcomes

Barratt Impulsivity Scale

Sponsors and collaborators

Lead sponsor

University of Minnesota

Other

Collaborators

Abbott
Schulz, S. Charles, M.D.

Registry information

Official study title

A Double-Blind and Placebo Controlled Assessment of Depakote ER in Borderline Personality Disorder

Important dates

Study start: 2003
Study completion: 2005
First posted: Sep 22, 2005
Registry last updated: Aug 9, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed